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Background: CRISPR-Cas9 is a revolutionary genome editing technique that allows for efficient and directed
alterations of the eukaryotic genome. This relatively new technology has already been used in a large number of
‘loss of function’ experiments in cultured cells. Despite its simplicity and efficiency, screening for mutated clones
remains time-consuming, laborious and/or expensive.
Results: Here we report a high-throughput screening strategy that allows parallel screening of up to 96 clones, using
next-generation sequencing. As a proof of principle, we used CRISPR-Cas9 to disrupt the coding sequence of the
homeobox gene, Evx1 in mouse embryonic stem cells. We screened 67 CRISPR-Cas9 transfected clones simultaneously
by next-generation sequencing on the Ion Torrent PGM. We were able to identify both homozygous and heterozygous
Evx1 mutants, as well as mixed clones, which must be identified to maintain the integrity of subsequent experiments.
Conclusions: Our CRISPR-Cas9 screening strategy could be widely applied to screen for CRISPR-Cas9 mutants in a
variety of contexts including the generation of mutant cell lines for in vitro research, the generation of transgenic
organisms and for assessing the veracity of CRISPR-Cas9 homology directed repair. This technique is cost and
time-effective, provides information on clonal heterogeneity and is adaptable for use on various sequencing
platforms.
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The recent development of genome editing techniques,
such as Zinc Finger Nucleases, TALENS and CRISPR-Cas9,
is revolutionizing the way that molecular biologists inter-
rogate the functionality of the eukaryotic genome. The
most exciting and rapidly expanding of these technologies,
CRISPR-Cas9 was only developed last year, yet it has
already had a huge impact on basic science research,
biotechnology and holds huge promise for medicine [1].
CRISPR-Cas9 genome editing is based on the type II
CRISPR adaptive immune pathway that is utilized by
Streptococcus pyogenes, to defend against bacteriophage
infection [2,3]. This simple two-part system consists
of a customizable guide RNA that directs the Cas9* Correspondence: charles.bell@mater.uq.edu.au
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unless otherwise stated.endonuclease to a genomic locus, causing double stranded
DNA breaks (DSB) [4]. These DSBs are subsequently
repaired through either, non-homologous end joining
(NHEJ) or homology directed repair (HDR), resulting
in the introduction of mutations into the targeted locus
[5]. By modifying this endogenous immune pathway,
CRISPR-Cas9 genome editing allows the generation of in-
sertion or deletion (indel) mutations, the deletion of large
genomic loci, such as entire exons, and the introduction
of specific small DNA changes, such as SNPs [4,6,7].
Other variant forms of Cas9 protein have also been
generated through mutation its catalytic domain. For
example, the catalytically inactive version of the Cas9
(dCas9) can be used to interfere with target gene expres-
sion, activate or overexpress target genes or visualize gen-
omic loci [8-11]. The relatively high efficiency and broad
applicability of this technology has opened the door
to experiments that were hitherto not possible. These
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works in a single experiment [7] and correcting disease
mutations in vivo [13]. These studies have and will
continue to provide insights into how the genome is
structured, regulated and can be modified to prevent
or cure disease.
In particular, CRISPR-Cas9 technology is ideal for
genetic engineering of cultured cells, as has been dem-
onstrated by its successful implementation in various
studies [5]. The entire experimental process from design
to the identification of mutant cell clones can be com-
pleted within 4 weeks, at a relatively low cost [6,14]. The
general CRISPR-Cas9 protocol for genetic engineering of
cultured cells involves: the design of guide RNAs to target
the locus of interest, construction of expression cassettes
containing Cas9 and the guide RNA, transfection of the
CRISPR-Cas9 construct into cells of interest, selection of
transfected-clones (optional), expansion of positive clones
in culture and finally screening for the desired CRISPR
induced mutations (described in detail in Ran et al. [6]).
The most time-consuming, labour intensive and costly
stage in the CRISPR-Cas9 methodology involves screening
and identification of mutant cell clones.
Currently CRISPR-Cas9 induced mutations are iden-
tified through PCR amplification of targeted regions
followed by cloning into plasmids and Sanger sequencing,
or deep sequencing using amplicon-based kits, such as the
Nextera XT DNA sequencing kit [6]. Plasmid cloning and
Sanger sequencing is time consuming, laborious, relatively
expensive and provides limited information on the hetero-
geneity of the clone, while the currently available deep
sequencing kits are relatively expensive and are specific to
particular sequencing platforms.
In this paper we propose a cheap, high-throughput
strategy for screening individual clones using next-
generation sequencing. We also demonstrate the utility
of this approach by identifying mutants for the homeobox
gene, Evx1 in mouse embryonic stem (mES) cells. This
method allows the screening of up to 96 clones in a
single sequencing run. In our methodology we use the
IonTorrent PGM, however this strategy is generalizable
and could also be adapted for use on other next-
generation sequencing platforms.
Results and discussion
Developing a cheap, high-throughput screening strategy
for CRISPR-Cas9
The preparation of barcoded DNA libraries is generally
achieved either through the ligation of unique barcode
and adaptor sequences to fragmented DNA [15], or by
incorporating barcode and adaptor sequences into PCR
primers, so that the barcodes and the appropriate adaptors
are added to the PCR product during the amplification
process [16]. The ligation strategy is generally utilizedwhen the sample contains a complex pool of DNA
fragments, or when the identity of the DNA fragments
is unknown, for example in a ChIPseq experiment.
Whereas, when the region to be sequenced is small
and the number of samples is large, it is practical to
incorporate barcodes and adaptors into “fusion” PCR
primers. However, “fusion primers” can become prohibi-
tively expensive as the number of samples to be sequenced
in parallel increases. Often over ~50-60 nucleotides in
length, they require more extensive purification steps to
ensure that the majority of the primers are full-length and
contain the complete sequencing adaptor sequences. In
order to create a more cost-effective amplicon library for
multiplexing a large number of CRISPR-Cas9 clones, we
used a hybrid approach, in which the DNA barcode is in-
cluded in the primer, along with a target specific sequence,
while the sequencing platform specific adaptors are ligated
in a subsequent reaction (Figure 1).
Since the NHEJ repair pathway results in indels of
various sizes at the CRISPR-Cas9 targeted site, we rea-
soned that screening primers should be designed to create
an amplicon over the targeted region and cover as much
of the surrounding DNA as possible. For the IonTorrent
PGM, we decided on an amplicon length of 200 bps,
maximizing our ability to detect a variety of mutations,
while ensuring that the majority of the reads reach the
forward and reverse barcode.
We used a row and column based barcoding system,
to reduce the number of primers required for screening.
By using 12 barcoded forward primers (columns) and 8
barcoded reverse primers (rows), it is possible to create a
uniquely barcoded amplicon for up to 96 clones (Figure 2).
We chose to use the barcode sequences from the pub-
lished IonXpress barcode set, as they have been optimized
to work with the flow set of bases used by the Ion Torrent
PGM. Using this barcoding system requires a total of only
20 primers, each approximately 30 nucleotides in length.
Screening for CRISPR-Cas9 induced mutations in Evx1
In order to demonstrate the applicability of our screening
strategy, we generated mutant mES cells for the homeo-
box gene, Evx1, which has previously been shown to be
dispensable for mouse embryonic development [17]. An
overview of our general screening methodology is shown
in Figure 2.
After transfection, sorting and expansion of CRISPR-
Cas9 targeted clones, we amplified the targeted region of
Evx1 using barcoded forward and reverse primers. We
validated the amplification of Evx1 in a number of clones
using one set of barcoded primers (Additional file 1:
Figure S1). Using the aforementioned strategy, we then
amplified 67 clones, each with a unique barcoded iden-
tity, in a 96 well plate format. DNA was pooled from
each of the wells in equal proportion, and quantified
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Figure 1 Barcoded library preparation strategy. Forward and reverse PCR primers were designed with a unique ~10 nt barcode along with
a ~20 nt site specific sequence, which will amplify around the CRISPR-Cas9 targeted site. In the first PCR cycle, either the forward or reverse barcode is
added to end of the PCR product. In the second PCR cycle, the opposite barcode is added to each PCR product. In each subsequent cycle, both the
forward and reverse barcodes are amplified along with the targeted region. After the PCR, sequencing platform specific adaptors are
ligated to the pool of barcoded amplicons in a single reaction.
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normalise the quantity of DNA from each PCR product,
as we reasoned the efficiency of PCR from each clone
would likely be similar and that even with discrepancies in
the concentration of DNA, we would achieve sufficient se-
quencing coverage of the least abundant clone to identify
the CRISPR induced mutations. Sequencing adaptors (Ion
Torrent A and P1) were ligated to the pooled DNA, and
the library was then sequenced on the IonTorrent PGM.
To determine the mutations present in each clone, it was
necessary to de-multiplex the samples. We achieved
this by writing a custom script in the R program-
ming language that makes use of the open source
‘ShortRead’ package available from the Bioconductor
website (http://www.bioconductor.org/). We applied this
script to our data, which produces a separate FastQ file
for each individual clone and then mapped all of the FastQ
files to mm9 using Bowtie2.
Sufficient coverage was achieved across all 67 clones,
enabling the identification of mutations in each clone.
The amplicon coverage varied from 313 fold to 6591
fold, with a mean coverage of 2455 fold (Additional
file 1: Figure S2). Over 95% of clones were covered
between 1/5th and 5 times the mean coverage indicat-
ing that our sequencing coverage was fairly uniform
and that equalization of the individual PCR products
was not required.
We visualized the data using Integrated Genomics
Viewer (IGV) version 2.3.34 and annotated the mutationsby visual inspection. Sequencing errors could easily be
distinguished from real indels by the fact that they show
an extreme strand bias and typically occur in the same
position in multiple samples [18,19] (Figure 3). Bona fide
mutations generally map in roughly equal proportions to
both strands (Figure 3B).
As has been reported previously, the incidence of
CRISPR-Cas9 induced mutations was very high (65 out
of 67 clones showing some form of genetic insult) and
all mutations were located close to the targeted sequence
[7] (Figure 3A). Our technique allowed us to distinguish
heterozygous mutants from homozygous mutants, as
well as identify samples that contained more than two
different types of mutations indicating a mixed clone.
Overall we identified 10 homozygous mutants, 27 com-
pound heterozygotes, 4 heterozygotes, 2 wildtypes, and
21 clones that showed more than two different alleles
(3 clones could not be mapped).
We suspect that the mixed clones are likely the result
of sorting multiple cells into a single well during the
FACS process or ongoing pCas9 activity after cell division,
resulting in different mutations in each daughter cell.
Importantly, using our screening method, we were able to
identify the presence of mixed clones, which could be
missed when screening using plasmid-cloning and Sanger
sequencing. Establishing the integrity of the derived clones
is essential for downstream analysis, especially when the
desired result is the complete disruption of the targeted
gene. Once identified, mixed clones can either be avoided
Figure 2 CRISPR-Cas9 screening workflow. Duplicate 96 well plates of cell clones are generated. One plate is frozen down or maintained for
later use. From the other plate, genomic DNA is extracted, and the targeted region is amplified and uniquely barcoded in each well. The DNA is
then pooled, adaptors ligated, and a fragment library is prepared. The sequencing library is then sequenced on the IonTorrent PGM. Reads are
filtered and visualized on IGV, to identify the desired clones. The desired clones are then thawed and/or expanded for subsequent experiments.
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serial dilution.
Conclusions
We developed a cheap, high-throughput screening strat-
egy for identifying CRISPR-Cas9 induced mutations using
next-generation sequencing. We successfully applied our
strategy to identify mES cell clones with a variety ofdifferent mutations in the homeobox gene, Evx1, using
the IonTorrent PGM. We found the frequency of
CRISPR-Cas9 induced mutations to be very high and
were able to identify 37 clones in which both alleles of
the Evx1 were disrupted. Our methodology has numerous
advantages over the current screening strategies. Firstly, it
is cost effective, as it requires only 20, 30 nt primers to
uniquely barcode up to 96 clones, additionally, as the
Figure 3 Visualization of CRISPR-Cas9 mutant clones. A) Coverage across the barcoded amplicon in a variety of different ‘knockout’
CRISPR-Cas9 clones. The wildtype clone has full coverage over the whole amplicon, while the mutant clones have variable indels
around the targeted site. Deletions are represented by a gap in the coverage, insertions are shown as black bars, while substitutions
are shown in red. Blue bars represent mismatched mapped reads, due to a large deletion. Brown bars show presumed sequencing
errors, which each have significant strand bias and commonly occur at the same position in multiple samples. B) The sequencing
reads and coverage for clone A6, which is a compound heterozygote with a 1 bp deletion on one allele and a 13 bp deletion on
the other allele. The deletions at the targeted site are present at equal proportion on both strands (blue and red), whereas the
sequencing error upstream is present only on the red strand.
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mutations are quite low, it is possible to multiplex
with additional samples. Secondly, this method is
generalizable, opening the door for deep sequencing-
based mutational screening on a variety of sequencing
platforms. Finally, our strategy provides information
on the heterogeneity of each clone (mixed clones),
which could be missed when screening with plasmid
cloning and Sanger sequencing.
Although in this study we have focused on screening
murine cells in culture, we envision that our strategy
could be widely applied to screen for CRISPR-Cas9
mutants, in a variety of contexts. Our strategy could beadapted to screen for mutants in CRISPR-Cas9 transgenic
organisms. It is also particularly well-suited for screening
mutations in polyploid organisms or cell lines, as next-
generation sequencing provides a global picture of all
alleles. This methodology provides a further step forward




W9.5 mES cells were routinely maintained in ES cell
media with LIF (1000 U/ml) on gelatinized tissue culture
plates at 37°C and 5% CO2.
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A guide RNA was designed to target the second exon of
Evx1, using the CRISPR-Cas9 design tool (crispr.mit.
edu.au). This guide was cloned into pCas9 (BB)2A-GFP
(Addgene PX458), as described previously [6].
Transfection, sorting and expansion of clones
W9.5 mES cells were electroporated using the BioRad
GenePulser II with pCas9-Evx1-2A-GFP plasmid according
to the manufacturer’s instructions. After 24 hours, mES
cells were dissociated with trypsin and FACS sorted on the
MoFlow Astrois Cell Sorter to enrich for GFP + cells. We
gated for cells that had high GFP expression (5% of the
original cell population) and sorted individual cells into 3
gelatinized 96 well plates, to allow for cell death in the
sorting and expansion process. Sorted cells were expanded
for a week and inspected to ensure that cells were present.
Two duplicate 96 well plates were generated from the
surviving clones, by transferring half of the clone to
one 96 well plate and the remaining half to another 96
well plate in the corresponding well. Once the clonal
cells were ~80% confluent in each 96 well plate, gen-
omic DNA was extracted from one of the plates using
a simple plate DNA extraction (outlined below). Cells
in the duplicate 96 well plate were frozen down in 10%
DMSO and stored at −80°C.
Plate genomic DNA extraction
Adherent cells in a 96 well plate were washed with PBS.
PBS was discarded and 50ul of lysis buffer (25 mM NaOH,
0.2 mM EDTA) was added to the cells. After 5 minutes of
rotating on an orbital shaker, cells were transferred to a 96
well PCR plate and heated at 95°C for 30 minutes. After
heating, 50 ul of Tris buffer (Tris–HCl 40 mM) was added
to make a final volume of 100 uL of genomic DNA.
Barcoded amplicon primer design and validation
Forward and reverse primers were designed to Evx1, 100
base pairs either side where the guide RNA was designed.
Unique barcodes were added to 12 forward and 8 reverse
primers to allow the unique barcoding of an entire 96 well
plate (Figure 1). Barcode sequences were taken from the
published IonXpress barcode set.
Sample barcoding and PCR amplification
5 uL was transferred from each well of the genomic
DNA plate to another 96 well PCR plate. 0.2 μM of the
barcoded forward and reverse primers to amplify the
targeted Evx1 locus were added to each well, along
with 1.5 mM MgCl2, 0.2 mM dNTPs, 10X PCR buffer
(−MgCl2) and platinum Taq DNA polymerase (Invitro-
gen). PCR was then conducted in the plate for 40 cycles
(95°C-2 min, 40 cycles of (95°C-30 sec, 55°C-30 sec,
72°C-30 sec), 72°C-30 sec).Library preparation
PCR products were combined in equal proportion
and the combined pool of PCR products was purified
in a single tube using Ampure XP reagent (#A63881,
Beckmann-Coulter) at 1.8X sample concentration, as per
the manufacturer’s instructions. Sequencing libraries were
created by ligating adaptor sequences to the pooled DNA
using the Ion Plus Fragment Library Kit (#4471252,
Life Technologies). Briefly, 50 ng of purified PCR prod-
uct was end-repaired and then A and P1 adaptors were
ligated. Amplicons with adaptors were purified with
Ampure XP reagent at 1.2X sample concentration.
Final library concentration was measured using the
Qubit fluorometer (#Q32866, Invitrogen) and the
double-stranded DNA high-sensitivity assay kit (#Q32854,
Invitrogen).
DNA sequencing
Libraries were diluted to 22 ng/mL (~100 pM) and se-
quencing template was prepared using the Ion PGM
Template OT2 200 kit (#4480974, Life Technologies) on
the Ion One Touch 2 instrument according to manufac-
turer’s instructions. Templated Ion Sphere Particles (ISPs)
were enriched on an Ion One Touch ES and sequencing
was performed on an Ion Torrent PGM along with
the Ion PGM Sequencing 200 Kit v2 (#4482006, Life
Technologies).
Sequence mapping
FastQ reads were mapped to the Mus musculus genome
version 9 (mm9) using Bowtie2 with default parameters,
apart from an adjustment to relax the gap extension pen-
alty (option: −-rdg 5,1). De-multiplexing of barcoded sam-
ples was performed in R using a custom script (Additional
file 2).
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